Direct Biologics Announces FDA Acceptance of IND Application for a Phase I/II Clinical Trial Studying ExoFlo for Acute Respiratory Distress Syndrome

AUSTIN, Texas: AUSTIN, Texas, July 14, 2021 /PRNewswire/ -- Direct Biologics, a market-leading innovator and cGMP manufacturer of regenerative biologic products, announced today that the U.S Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to conduct a Phase I/II clinical trial using ExoFlo™ in the...

Click to view original post